According to GlaxoSmithKline, the company has submited a new drug application (NDA) to the US FDA for a once-daily fluticasone furoate (FF) dry powder inhaler for the treatment of asthma. The NDA is for 100mcg and 200mcg doses of FF delivered by the Ellipta DPI.
GSK says that it will submit applications for FF monotherapy in other countries beginning in 2014.
Read the GSK press release.
